ARWR
Income statement / Annual
Last year (2023), Arrowhead Pharmaceuticals, Inc.'s total revenue was $240.74 M,
a decrease of 1.03% from the previous year.
In 2023, Arrowhead Pharmaceuticals, Inc.'s net income was -$205.28 M.
See Arrowhead Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
| Operating Revenue |
$240.74 M
|
$243.23 M
|
$138.29 M
|
$87.99 M
|
$168.80 M
|
$16.14 M
|
$31.41 M
|
$158,333.00
|
$382,000.00
|
$175,000.00
|
| Cost of Revenue |
$12.49 M |
$10.42 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$228.24 M |
$232.81 M |
$138.29 M |
$87.99 M |
$168.80 M |
$16.14 M |
$31.41 M |
$158,333.00 |
$382,000.00 |
$175,000.00 |
| Gross Profit Ratio |
0.95 |
0.96 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$353.19 M
|
$297.31 M
|
$206.34 M
|
$128.87 M
|
$81.05 M
|
$52.97 M
|
$31.69 M
|
$41.45 M
|
$57.41 M
|
$23.14 M
|
| General & Administrative
Expenses |
$92.55 M
|
$124.43 M
|
$80.98 M
|
$52.28 M
|
$26.56 M
|
$19.11 M
|
$32.02 M
|
$41.00 M
|
$34.72 M
|
$24.42 M
|
| Selling & Marketing
Expenses |
$19.68 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$92.55 M
|
$124.43 M
|
$80.98 M
|
$52.28 M
|
$26.56 M
|
$19.11 M
|
$32.02 M
|
$41.00 M
|
$34.72 M
|
$24.42 M
|
| Other Expenses |
$1.54 M |
$5.80 M |
$2.07 M |
-$582,524.00 |
$0.00 |
$7,493.00 |
$1.31 M |
$57,352.00 |
$417,874.00 |
$82,092.00 |
| Operating Expenses |
$445.74 M |
$421.74 M |
$287.32 M |
$181.15 M |
$107.60 M |
$72.08 M |
$68.40 M |
$79.85 M |
$96.36 M |
$51.28 M |
| Cost And Expenses |
$445.74 M |
$421.74 M |
$287.32 M |
$181.15 M |
$107.60 M |
$72.08 M |
$68.40 M |
$79.85 M |
$96.36 M |
$51.28 M |
| Interest Income |
$15.30 M |
$5.03 M |
$6.12 M |
$9.19 M |
$6.96 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$18.33 M |
$5.03 M |
$6.12 M |
$9.19 B |
$6.96 B |
$1.05 B |
$415.13 M |
$265.79 M |
$729.16 M |
$645.49 M |
| Depreciation &
Amortization |
$12.49 M
|
$10.42 M
|
$8.27 M
|
$5.94 M
|
$4.44 M
|
$4.70 M
|
$4.69 M
|
$3.26 M
|
$2.34 M
|
$1.35 M
|
| EBITDA |
-$188.17 M
|
-$178.51 M
|
-$140.77 M
|
-$87.22 M
|
$65.63 M
|
-$51.67 M
|
-$33.20 M
|
-$74.08 M
|
-$96.53 M
|
-$41.49 M
|
| EBITDA Ratio |
-0.78 |
-0.73 |
-1.02 |
-0.99 |
0.39 |
-3.2 |
-1.06 |
-467.87 |
-252.69 |
-237.1 |
| Operating Income Ratio
|
-0.85
|
-0.73
|
-1.08
|
-1.06
|
0.36
|
-3.47
|
-1.18
|
-516.27
|
-251.24
|
-304.44
|
| Total Other
Income/Expenses Net |
$1.54 M
|
$5.80 M
|
$8.19 M
|
$8.61 M
|
$6.96 M
|
$439,634.00
|
$2.20 M
|
-$2.29 M
|
$3.31 M
|
-$8.26 M
|
| Income Before Tax |
-$206.49 M |
-$172.71 M |
-$140.85 M |
-$84.55 M |
$68.15 M |
-$54.45 M |
-$34.38 M |
-$81.72 M |
-$91.94 M |
-$58.72 M |
| Income Before Tax Ratio
|
-0.86
|
-0.71
|
-1.02
|
-0.96
|
0.4
|
-3.37
|
-1.09
|
-516.13
|
-240.68
|
-335.54
|
| Income Tax Expense |
$2.78 M |
$3.79 M |
$2,000.00 |
$2,400.00 |
$173,553.00 |
$2,400.00 |
$2,400.00 |
$2,400.00 |
$2,400.00 |
$5,300.00 |
| Net Income |
-$205.28 M |
-$176.49 M |
-$140.85 M |
-$84.55 M |
$67.97 M |
-$54.45 M |
-$34.38 M |
-$81.72 M |
-$91.94 M |
-$58.63 M |
| Net Income Ratio |
-0.85 |
-0.73 |
-1.02 |
-0.96 |
0.4 |
-3.37 |
-1.09 |
-516.15 |
-240.68 |
-335.03 |
| EPS |
-1.92 |
-1.67 |
-1.36 |
-0.84 |
0.72 |
-0.65 |
-0.47 |
-1.34 |
-1.6 |
-1.25 |
| EPS Diluted |
-1.92 |
-1.67 |
-1.36 |
-0.84 |
0.69 |
-0.65 |
-0.47 |
-1.34 |
-1.6 |
-1.25 |
| Weighted Average Shares
Out |
$106.75 M
|
$105.43 M
|
$103.75 M
|
$100.72 M
|
$93.86 M
|
$83.64 M
|
$73.15 M
|
$60.99 M
|
$57.36 M
|
$46.90 M
|
| Weighted Average Shares
Out Diluted |
$106.75 M
|
$105.43 M
|
$103.75 M
|
$100.72 M
|
$98.61 M
|
$83.64 M
|
$73.90 M
|
$61.05 M
|
$57.36 M
|
$46.93 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
